Hemin, a previously Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved drug for acute intermittent porphyria treatment [8,9], is a well known inducer of HO-1 that increases its plasma concentration in humans. This evidence concerns the gene HMOX1 and acute intermittent porphyria.